Hemispherx Biopharma, based in Philadelphia, PA, is a biopharmaceutical company focused on developing innovative solutions for a range of debilitating and life-threatening conditions. Their lead program, Ampligen, is an immuno-modulator that has shown broad-spectrum activity in in vitro and animal testing, with ongoing clinical studies for oncology, immune disorders, and viral diseases.
The company is dedicated to advancing therapeutic solutions with the potential to improve patients' lives across various disease areas. Hemispherx Biopharma aims to provide cutting-edge treatments through their research and development efforts, including collaborations and clinical trials to address critical medical needs.
Generated from the website